Interleukin-18 and cardiovascular diseases: a literature review

Cardiovascular disease is a serious problem of modern healthcare, which one the leading causes general mortality, reduction and loss ability to work, as well disability. The search study new cardiovascular biological markers can allow optimization diagnosis diseases, development laboratory tools for assessing effectiveness treatment, improving prediction possible adverse clinical outcomes. purpose this review was promote consideration interleukin-18 (IL-18) diagnostic prognostic marker in pathology. For first time, K. Nakamura et al. 1989, described IL-18 interferon-gamma (IFN--inducing factor, IFN--inducing IGIF) new, previously unknown factor that induces production IFN-. Data obtained from rodent models studies have demonstrated involved pathogenesis several immune-inflammatory rheumatic conditions, systemic vasculitis, malignancy, central nervous system pathologies, inflammatory bowel disease, psoriasis, diseases kidneys lungs. In animal acute myocardial infarction, pressure overload, left ventricular dysfunction, has been increase cardiomyocyte hypertrophy, induce cardiac contractile extracellular matrix remodeling. It therefore expected further scientific demonstrate possibility using an additional tool diagnosis, risk stratification, events patients with profile. effect blockade cytokine on reducing morbidity mortality remains be assessed more detail, while considering reasonable economic costs side effects drugs.